NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Olema Pharmaceuticals reported Q2 2025, net loss of $110M, diluted EPS of $-1.25.
For Q2 2025, Olema Pharmaceuticals reported a net loss of $110M, diluted EPS was $-1.25. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $110M.
- Diluted EPS $-1.25.
- Olema Pharmaceuticals MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Clinical-stage and growth biotech discuss trial milestones, cash runway, and partnership optionality.
Tailwinds
- Pipeline progress and data readouts.
- Cash runway from recent financings.
- Licensing or collaboration potential.
Headwinds
- Trial failure or regulatory delays.
- Dilution from equity raises.
- Commercialization timing uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro